Coherus BioSciences, Inc. (NASDAQ:CHRS)

CAPS Rating: 3 out of 5

Results 1 - 3 of 3

Recs

0
Member Avatar murphydevani (65.23) Submitted: 8/21/2015 9:08:55 AM : Underperform Start Price: $28.55 CHRS Score: +0.64

Target $27 - $25 - $21

Recs

0
Member Avatar km00nster (< 20) Submitted: 4/16/2015 12:03:33 AM : Outperform Start Price: $28.42 CHRS Score: +2.22

As drugs get more expensive, biosimilars are going to provide a cheaper alternative. Coherus provides a pure play at a reasonable price. They just had a sec offering at 29 dollars a share. Purchased shares on this dip. Huge growth and a huge market (20 BILL). OUTPERFORM.

Recs

1
Member Avatar usubanas (99.75) Submitted: 1/13/2015 12:18:05 PM : Outperform Start Price: $22.43 CHRS Score: +26.22

Good management with lots of experience. Seems to be under the radar, but biosimilars time is finally coming...

Results 1 - 3 of 3

Featured Broker Partners